GeoVax reports 2023 net loss of $26.0M, cash drops to $6.5M; pipeline advances

GeoVax Labs, Inc.

Net loss widened to $26.0M in 2023 from $14.0M in 2022, driven by higher R&D costs ($20.7M vs $9.1M).
Cash balance fell to $6.5M at Dec 31, 2023, from $27.6M a year earlier, reflecting clinical spending.
Phase 2 trials of Covid vaccine GEO-CM04S1 continue; interim CLL booster data expected H1 2024.
Gedeptin Phase 1/2 for head & neck cancer completed; expanded Phase 2 plans anticipated in 2024.
Appointed Dr. J. Marc Pipas as Executive Medical Director, Oncology, to lead clinical development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

GeoVax Labs, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2023.

View on SEC.gov

4 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-006289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.